Antibodies to PCSK9: A superior way to lower LDL cholesterol?

Circulation Research

Volumn 111, Issue 3, 2012, Pages 274-277

  Maxwell, Kara N ^a   Breslow, Jan L ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ATORVASTATIN; EZETIMIBE; FOMIVERSIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MIPOMERSEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY REGN 727; PROTEIN PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; REGN 727; SODIUM CHANNEL; TORCETRAPIB; UNCLASSIFIED DRUG;

ANTISENSE THERAPY; APOPTOSIS; ARTERIAL WALL THICKNESS; ATHEROSCLEROTIC PLAQUE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CORONARY ARTERY ATHEROSCLEROSIS; CYTOMEGALOVIRUS RETINITIS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; ENZYME ACTIVITY; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC TRANSCRIPTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MORTALITY; MULTIPLE CYCLE TREATMENT; NONHUMAN; NOTE; PANCREAS ISLET CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RNA INTERFERENCE; SAMPLE SIZE; SCIENCE; SINGLE DRUG DOSE;

EID: 84864206454     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.112.275859     Document Type: Note

References (24)

1. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108-1118.
2. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, Goldstein JL. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A. 2003;100:12027-12032. (Pubitemid 37271509)
3. Maxwell KN, Soccio RE, Duncan EM, Sehayek E, Breslow JL. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res. 2003;44:2109-2119. (Pubitemid 37509626)
4. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003;100: 928-933. (Pubitemid 36183932)
5. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-156. (Pubitemid 36666925)
6. Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A. 2005;102:2069-2074. (Pubitemid 40262013)
7. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest. 2006;116:2995-3005. (Pubitemid 44684484)
8. Grefhorst A, McNutt MC, Lagace TA, Horton JD. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res. 2008;49: 1303-1311.
9. Maningat P, Breslow JL. Needed: pragmatic clinical trials for statinintolerant patients. N Engl J Med. 2011;365:2250-2251.
10. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
11. McNutt MC, Lagace TA, Horton JD. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HEPG2 cells. J Biol Chem. 2007;282:20799-20803. (Pubitemid 47099894)
12. Visser ME, Wagener G, Baker BF, Geary RS, Donovan JM, Beuers UH, Nederveen AJ, Verheij J, Trip MD, Basart DC, Kastelein JJ, Stroes ES. Mipomersen, an apolipoprotein b synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012;33: 1142-1149.
13. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAI targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A. 2008;105:11915-11920.
14. Graham MJ, Lemonidis KM, Whipple CP, Subramaniam A, Monia BP, Crooke ST, Crooke RM. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum ldl in hyperlipidemic mice. J Lipid Res. 2007;48:763-767. (Pubitemid 46557881)
15. Lindholm MW, Elmen J, Fisker N, Hansen HF, Persson R, Moller MR, Rosenbohm C, Orum H, Straarup EM, Koch T. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther. 2012;20:376-381.
16. Duff CJ, Scott MJ, Kirby IT, Hutchinson SE, Martin SL, Hooper NM. Antibody-mediated disruption of the interaction between pcsk9 and the low-density lipoprotein receptor. Biochem J. 2009;419:577-584.
17. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, sar236553/regn727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344-2353.
18. Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A. 2009;106:9820-9825.
19. Liang H, Chaparro-Riggers J, Strop P, et al. Proprotein convertase substilisin/ kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statintreated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther. 2012;340:228-236.
20. Ni YG, Di Marco S, Condra JH, et al. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res. 2011;52:78-86.
21. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431-1443. (Pubitemid 351482735)
22. Denis M, Marcinkiewicz J, Zaid A, Gauthier D, Poirier S, Lazure C, Seidah NG, Prat A. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation. 2012;125:894-901.
23. Kathiresan S, Voight BF, Purcell S, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009;41:334-341.
24. Califf RM, Lokhnygina Y, Cannon CP, Stepanavage ME, McCabe CH, Musliner TA, Pasternak RC, Blazing MA, Giugliano RP, Harrington RA, Braunwald E. An update on the improved reduction of outcomes: Vytorin efficacy international trial (improve-it) design. Am Heart J. 2010;159: 705-709.